Cambrex Corp. announced Wednesday it has made three senior-level appointments.
The appointments, the East Rutherford-based pharmaceutical product developer said, will support the company’s strategy to create a Contract Development and Manufacturing Organization for small molecules.
The appointments are as follows:
- Bruno Biscaro has been named president, drug products;
- Joe Nettleton has been named president, drug substance;
- Simon Edwards has been named as president, CDMO sales and marketing.
Biscaro, who has more than 30 years of experience in pharmaceutical leadership, will be responsible for the company’s drug product business. Prior to Cambrex, he was president, North America at Famar. Before that, he was president of Accucaps Industries and held numerous leadership roles at GlaxoSmithKline.
Nettleton will be tasked with operating Cambrex’s Charles City, Iowa; Karlskoga, Sweden; Wiesbaden, Germany; and Tallinn, Estonia facilities. Nettleton previously served as vice president, U.S. operations and has been with Cambrex for 28 years.
Edwards will be responsible for providing customers with a single point of contact for its CDMO services as well as help drive commercial activity and brand recognition.
“I’m delighted to announce these appointments that underpin our strategy to be the leading small molecule company with the ability to serve customers across the entire drug lifecycle,” Shawn Cavanagh, executive vice president and chief operating officer, said. “Our recent acquisitions of Avista and Halo align with this strategy and leverages our core strengths, while positioning us as a leading global provider of end-to-end integrated services for small molecules. These appointments play a crucial role in Cambrex delivering a wider range of services to new and existing customers.”
